Drugs / piperacillin/tazobactam
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT02191475 | May 2014 → May 2017 | digestive system infectious disorder | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | piperacillin/tazobactam | “piperacillin / tazobactam 4.5g, ivdrip, 3-4 times a day” NCT02191475 ↗ |
| Known as | tazocin | “piperacillin / tazobactam (tazocin ®), with or without antifungal therapy” NCT02191475 ↗ |
| Modality | Other / unclassified | “Piperacillin / tazobactam also is a broad spectrum, potent antibiotics” NCT02191475 ↗ |
| Route | Intravenous | “piperacillin / tazobactam 4.5g, ivdrip, 3-4 times a day” NCT02191475 ↗ |